Troubling podcast puts JAMA, the ‘voice of medicine,’ under fire for its mishandling of race
By Usha Lee McFarling,
STAT
| 04. 06. 2021
Weeks after it was scrubbed from the Journal of the American Medical Association’s website, a disastrous podcast — whose host, a white editor and physician, questioned whether racism even exists in medicine — is surfacing complaints that JAMA and other elite medical journals have routinely excluded, minimized, and mishandled issues of race.
Recent examples include research blaming higher death rates from Covid-19 in African Americans on a single gene in their nasal passages; a letter claiming structural racism doesn’t play a role in pulse oximeters working less well on patients with dark skin because machines can’t exhibit bias; and an article claiming that students of programs designed to increase diversity in medicine won’t make good doctors.
Critics say such ideas, published in powerful journals that doctors look to for leadership and education, are serving to perpetuate and entrench health inequities that have long harmed and shortened the lives of many people of color.
“It’s the voice of medicine. They set the priorities,” said Brittani James, an assistant professor of clinical family medicine at the University of Illinois College of Medicine...
Related Articles
By Emily Baumgaertner Nunn, The New York Times | 09.08.2026
It is one of biology’s most ingenious rhythms: Every baby is born young. No matter how much wear and tear their parents’ DNA accumulated over their lifetimes, reproduction erases the molecular scars, handing a clean slate to the next generation...
What We Inherit by Sam Trejo and Daphne O. Martschenko; and Original Sin by Kathryn Paige Harden have a great deal in common, with substantial differences in style and emphasis. Both books attempt, in different ways, to show the reader just where current research into human genomics stands, where that might be going, and why the authors are interested. In short, the influence of genomic research on our societies is already large and seems likely to change them in ways...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Jessica Hamzelou, MIT Technology Review | 07.23.2026
When it comes to organ donation, time is everything. As soon as an organ has been carefully removed from a donor’s body, it starts to deteriorate. Surgeons have a matter of hours to get it into a recipient. Leave...